Christine Brown

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9534422/publications.pdf

Version: 2024-02-01

108 papers	10,143 citations	38742 50 h-index	37204 96 g-index
114 all docs	114 docs citations	114 times ranked	11183 citing authors

#	Article	IF	Citations
1	Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. New England Journal of Medicine, 2016, 375, 2561-2569.	27.0	1,326
2	Bioactivity and Safety of IL13RÎ±2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2015, 21, 4062-4072.	7.0	573
3	Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells. Cancer Research, 2004, 64, 9160-9166.	0.9	342
4	Recruitment of HAT Complexes by Direct Activator Interactions with the ATM-Related Tra1 Subunit. Science, 2001, 292, 2333-2337.	12.6	334
5	The many HATs of transcription coactivators. Trends in Biochemical Sciences, 2000, 25, 15-19.	7.5	325
6	T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, 2013, 122, 3138-3148.	1.4	322
7	Phase 1 studies of central memoryâ€“derived CD19 CAR Tâ€“cell therapy following autologous HSCT in patients with B-cell NHL. Blood, 2016, 127, 2980-2990.	1.4	264
8	Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science Translational Medicine, 2017, 9, .	12.4	263
9	IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunology Research, 2019, 7, 759-772.	3.4	235
10	Regional Delivery of Chimeric Antigen Receptorâ€“Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Clinical Cancer Research, 2018, 24, 95-105.	7.0	220
11	Optimization of IL13RÎ±2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Molecular Therapy, 2018, 26, 31-44.	8.2	217
12	Poly(A) Tail Length Control in Saccharomyces cerevisiae Occurs by Message-Specific Deadenylation. Molecular and Cellular Biology, 1998, 18, 6548-6559.	2.3	197
13	Neural Stem Cellâ€“Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies. Science Translational Medicine, 2013, 5, 184ra59.	12.4	194
14	Stem-like Tumor-Initiating Cells Isolated from IL13RÎ±2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakineâ€“Redirected T Cells. Clinical Cancer Research, 2012, 18, 2199-2209.	7.0	191
15	Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy. Molecular Therapy, 2015, 23, 757-768.	8.2	169
16	Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Frontiers in Immunology, 2017, 8, 1850.	4.8	161
17	Transcription Activator Interactions with Multiple SWI/SNF Subunits. Molecular and Cellular Biology, 2002, 22, 1615-1625.	2.3	160
18	Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Molecular Immunology, 2012, 51, 263-272.	2.2	158

#	Article	IF	Citations
19	Targeting Alpha-Fetoprotein (AFP)â€“MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clinical Cancer Research, 2017, 23, 478-488.	7.0	158
20	CAR T cells for brain tumors: Lessons learned and road ahead. Immunological Reviews, 2019, 290, 60-84.	6.0	151
21	Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight, 2018, 3, .	5.0	150
22	Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Science Translational Medicine, 2020, 12, .	12.4	150
23	PAN3 Encodes a Subunit of the Pab1p-Dependent Poly(A) Nuclease in Saccharomyces cerevisiae. Molecular and Cellular Biology, 1996, 16, 5744-5753.	2.3	149
24	CAR T cell therapy: inroads to response and resistance. Nature Reviews Immunology, 2019, 19, 73-74.	22.7	148
25	Capped mRNA Degradation Intermediates Accumulate in the Yeast spb8-2 Mutant. Molecular and Cellular Biology, 1998, 18, 5062-5072.	2.3	142
26	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptorâ€“Redirected T Cells Against Multiple Myeloma. Clinical Cancer Research, 2018, 24, 106-119.	7.0	136
27	Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells. Journal of Immunology, 2007, 179, 3332-3341.	0.8	133
28	Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncology, 2014, 16, 1304-1312.	1.2	131
29	Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nature Communications, 2020, 11, 2283.	12.8	130
30	Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale. Journal of Immunotherapy, 2012, 35, 689-701.	2.4	128
31	The yeast SAS (something about silencing) protein complex contains a MYST-type putative acetyltransferase and functions with chromatin assembly factor ASF1. Genes and Development, 2001, 15, 3155-3168.	5.9	127
32	Glioma IL13RÎ±2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis. PLoS ONE, 2013, 8, e77769.	2.5	126
33	Recognition and Killing of Brain Tumor Stem-Like Initiating Cells by CD8+ Cytolytic T Cells. Cancer Research, 2009, 69, 8886-8893.	0.9	118
34	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. OncoImmunology, 2018, 7, e1380764.	4.6	111
35	PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with ⁸⁹Zr-Oxine. Journal of Nuclear Medicine, 2018, 59, 1531-1537.	5.0	111
36	Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3. Molecular Cancer Therapeutics, 2010, 9, 953-962.	4.1	110

#	Article	IF	Citations
37	Genome-Wide Profiling Identified a Set of miRNAs that Are Differentially Expressed in Glioblastoma Stem Cells and Normal Neural Stem Cells. PLoS ONE, 2012, 7, e36248.	2.5	100
38	Magnetic Resonance Imaging Tracking of Ferumoxytol-Labeled Human Neural Stem Cells: Studies Leading to Clinical Use. Stem Cells Translational Medicine, 2013, 2, 766-775.	3.3	88
39	IFNÎ³ Is Critical for CAR T Cellâ€“Mediated Myeloid Activation and Induction of Endogenous Immunity. Cancer Discovery, 2021, 11, 2248-2265.	9.4	86
40	Chimeric antigen receptor signaling: Functional consequences and design implications. Science Advances, 2020, 6, eaaz3223.	10.3	81
41	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. Cancer Discovery, 2021, 11, 1192-1211.	9.4	78
42	Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 3037-3048.	4.1	71
43	Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. Nature Communications, 2016, 7, 10637.	12.8	67
44	Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy. Clinical Cancer Research, 2010, 16, 3399-3408.	7.0	63
45	Smart CARs engineered for cancer immunotherapy. Current Opinion in Oncology, 2015, 27, 466-474.	2.4	63
46	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Advances, 2021, 5, 4059-4063.	5.2	62
47	TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting. Cancer Research, 2014, 74, 5218-5228.	0.9	60
48	Unique challenges for glioblastoma immunotherapyâ€”discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
49	Neural Stem Cell-Mediated Delivery of Irinotecan-Activating Carboxylesterases to Glioma: Implications for Clinical Use. Stem Cells Translational Medicine, 2013, 2, 983-992.	3.3	58
50	Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. Journal of the Royal Society Interface, 2020, 17, 20190734.	3.4	58
51	Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. Journal of Immunological Methods, 2005, 297, 39-52.	1.4	57
52	A Novel Berbamine Derivative Inhibits Cell Viability and Induces Apoptosis in Cancer Stem-Like Cells of Human Glioblastoma, via Up-Regulation of miRNA-4284 and JNK/AP-1 Signaling. PLoS ONE, 2014, 9, e94443.	2.5	57
53	3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR TÂcells. Cell Stem Cell, 2022, 29, 515-527.e8.	11.1	57
54	Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Therapy, 2007, 14, 91-97.	4.6	52

#	Article	IF	Citations
55	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clinical Cancer Research, 2015, 21, 2993-3002.	7.0	52
56	Diverse Solid Tumors Expressing a Restricted Epitope of L1-CAM Can Be Targeted by Chimeric Antigen Receptor Redirected T Lymphocytes. Journal of Immunotherapy, 2014, 37, 93-104.	2.4	50
57	Histone Acetyltransferase Complexes and Their Link to Transcription. Critical Reviews in Eukaryotic Gene Expression, 1999, 9, 231-243.	0.9	44
58	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. , 2021, 9, e002181.		42
59	Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy. Frontiers in Immunology, 2021, 12, 635173.	4.8	41
60	Medulloblastomas Expressing IL13RÎ±2 are Targets for IL13-zetakine+ Cytolytic T Cells. Journal of Pediatric Hematology/Oncology, 2007, 29, 669-677.	0.6	37
61	L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. PLoS ONE, 2016, 11, e0146885.	2.5	34
62	Off-the-shelf, steroid-resistant, IL13RÎ±2-specific CAR T cells for treatment of glioblastoma. Neuro-Oncology, 2022, 24, 1318-1330.	1.2	32
63	Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. Nature Communications, 2022, 13, .	12.8	29
64	Systemic Antiâ€“PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. JAMA Oncology, 2020, 6, 1947.	7.1	28
65	Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. OncoImmunology, 2021, 10, 1899469.	4.6	28
66	Chimeric antigen receptor T-cell therapy for glioblastoma. Translational Research, 2017, 187, 93-102.	5.0	27
67	Comparison of naÃ¯ve and central memory derived CD8⁺effector cell engraftment fitness and function following adoptive transfer. OncoImmunology, 2016, 5, e1072671.	4.6	25
68	Engineering Human T Cells for Resistance to Methotrexate and Mycophenolate Mofetil as an In Vivo Cell Selection Strategy. PLoS ONE, 2013, 8, e65519.	2.5	25
69	Human Neural Stem Cell Biodistribution and Predicted Tumor Coverage by a Diffusible Therapeutic in a Mouse Glioma Model. Stem Cells Translational Medicine, 2017, 6, 1522-1532.	3.3	24
70	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. Cancer Immunology Research, 2021, 9, 75-88.	3.4	24
71	Integrin Î±6 signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells. Oncogene, 2020, 39, 2156-2169.	5.9	23
72	Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase. Gene Therapy, 2013, 20, 853-860.	4.5	22

#	Article	IF	Citations
73	A metabolic switch to memory CAR T cells: Implications for cancer treatment. Cancer Letters, 2021, 500, 107-118.	7.2	21
74	Next frontiers in CAR T-cell therapy. Molecular Therapy - Oncolytics, 2016, 3, 16028.	4.4	20
75	In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function. Journal of Visualized Experiments, 2019, , .	0.3	19
76	Chimeric Antigen Receptor T-Cell Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1092-1106.	4.9	15
77	T-cell genetic modification for re-directed tumor recognition. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 293-324.	0.5	15
78	Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models. International Journal of Molecular Sciences, 2022, 23, 3154.	4.1	15
79	Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. Neurosurgery, 2021, 88, 1056-1064.	1.1	14
80	A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells. Journal of Immunological Methods, 2005, 302, 78-89.	1.4	12
81	Chimeric Î³c cytokine receptors confer cytokine independent engraftment of human T lymphocytes. Molecular Immunology, 2013, 56, 1-11.	2.2	12
82	Mitochondria as Playmakers of CAR T-cell Fate and Longevity. Cancer Immunology Research, 2021, 9, 856-861.	3.4	12
83	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?. Frontiers in Immunology, 2021, 12, 765906.	4.8	12
84	Adult Patients with ALL Treated with CD62L+ T NaÃ¯ve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile. Blood, 2018, 132, 4016-4016.	1.4	11
85	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. Blood, 2019, 134, 4075-4075.	1.4	10
86	Acute myeloid leukemia therapeutics. OncoImmunology, 2013, 2, e27214.	4.6	9
87	CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL. Blood, 2018, 132, 610-610.	1.4	9
88	Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers. Drug Delivery and Translational Research, 2021, 11, 2448-2467.	5.8	8
89	Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy. PLoS Computational Biology, 2022, 18, e1009504.	3.2	8
90	Loss of SIRT1 inhibits hematopoietic stem cell aging and age-dependent mixed phenotype acute leukemia. Communications Biology, 2022, 5, 396.	4.4	7

#	Article	IF	Citations
91	The future of cancer immunotherapy for brain tumors: a collaborative workshop. Journal of Translational Medicine, 2022, 20, .	4.4	7
92	Cytotoxic T Lymphocyte Trafficking and Survival in an Augmented Fibrin Matrix Carrier. PLoS ONE, 2012, 7, e34652.	2.5	6
93	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. NeuroMolecular Medicine, 2022, 24, 35-40.	3.4	6
94	Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells. , 2022, 10, e003752.		4
95	Contact and Encirclement of Glioma Cells In Vitro Is an Intrinsic Behavior of a Clonal Human Neural Stem Cell Line. PLoS ONE, 2012, 7, e51859.	2.5	3
96	Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab174.	0.7	3
97	IMMU-08. THERAPEUTIC POTENTIAL OF CHLOROTOXIN-REDIRECTED CAR-T CELLS AGAINST HETEROGENEOUS GLIOBLASTOMAS. Neuro-Oncology, 2017, 19, vi114-vi114.	1.2	2
98	Abstract PO083: Treatment of CEA-positive solid tumors with anti-CEA chimeric antigen receptor T-cells in CEA transgenic mice. Cancer Immunology Research, 2021, 9, PO083-PO083.	3.4	2
99	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. Blood, 2015, 126, 930-930.	1.4	2
100	Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma. Neoplasia, 2022, 30, 100801.	5.3	2
101	CD123-Specific Chimeric Antigen Receptor Redirected T Cells Exhibit Potent Cytolytic Activity and Multiple Effector Functions Against Acute Myeloid Leukemia without Altering Normal Hematopoietic Colony Formation in Vitro. Blood, 2012, 120, 950-950.	1.4	1
102	CS-1 Re-Directed Central Memory T Cell Therapy for Multiple Myeloma. Blood, 2014, 124, 1114-1114.	1.4	1
103	Cytokine Induction of VCAM-1 but Not IL13RÎ±2 on Glioma Cells: A Tale of Two Antibodies. PLoS ONE, 2014, 9, e95123.	2.5	1
104	Abstract CT541A: Oncolytic viral reshaping of the tumor microenvironment to promote CAR T cell therapy for glioblastoma. Cancer Research, 2022, 82, CT541A-CT541A.	0.9	1
105	Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. Blood, 2015, 126, 3086-3086.	1.4	0
106	New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. Blood, 2016, 128, 2161-2161.	1.4	0
107	EXTH-10. EXPLORATION OF A NOVEL TOXIN-INCORPORATING CAR T CELL: HOW DOES CHLOROTOXIN RECOGNIZE GLIOBLASTOMA CELLS?. Neuro-Oncology, 2021, 23, vi165-vi165.	1.2	0
108	CTIM-29. CLINICAL EVALUATION OF CHLOROTOXIN-DIRECTED CAR T CELLS FOR PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi57-vi57.	1.2	0